September 11th 2024
EASD 2024: New data shows survodutide may be beneficial for persons with obesity and MASH.
June 17th 2024
Your daily dose of the clinical news you may have missed.
June 13th 2024
More than 50% of patients with MASH receiving 1 of 3 doses of tirzepatide achieved MASH resolution without worsening of fibrosis vs placebo, according to data from phase 2 study.
June 11th 2024
June 4th 2024
ENDO 2024. New findings suggest GLP-1RAs and SGLT-2is may be more beneficial than other diabetes agents for patients with T2D and MASLD.